Department of Urology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
J Urol. 2011 Oct;186(4):1303-7. doi: 10.1016/j.juro.2011.05.084.
We present our experience with penile sparing surgery for localized carcinoma in situ and T1 penile squamous cell carcinoma. We report outcomes and recommendations for a penile sparing approach.
A total of 60 patients underwent penile sparing surgery for penile squamous cell carcinoma since 1995. Four patients without recurrence had less than 6 months of followup and were excluded from study. Data included disease stage, cellular differentiation, tumor site, penile sparing surgery type and recurrence information.
Followup was adequate in 28 patients with carcinoma in situ and in 28 with T1 disease. The overall recurrence rate was 21.4% with equal recurrences of carcinoma in situ and T1 tumors (each 21.4%). Mean ± SD time to recurrence was 4.28 ± 2.81 years (range 0.5 to 11). More than 25% of recurrences developed after 5 years. Mean followup in censored patients was 5.47 ± 3.88 years (maximum 16). There was no difference in time to recurrence after carcinoma in situ and T1 tumors (p = 0.738). T1 tumors on the glans carried a slightly higher risk of recurrence (p = 0.049). At 5 years 13.8% of patients at risk had late recurrence with a mean time to recurrence of 7.25 ± 2.62 years. No patients with carcinoma in situ showed invasion or metastasis. Two patients with T1 disease presented with metastasis and 3 had late metastasis.
Penile sparing surgery is a safe option for local control for appropriate carcinoma in situ and T1 squamous cell carcinoma of the penis. Carcinoma in situ recurrence may be re-treated with penile sparing surgery. T1 tumors that recur require more aggressive resection. Our data show significant late recurrences in patients and the need for long-term followup.
我们介绍了我们在局部原位癌和 T1 阴茎鳞状细胞癌中进行保留阴茎手术的经验。我们报告了保留阴茎方法的结果和建议。
自 1995 年以来,共有 60 例阴茎鳞状细胞癌患者接受了保留阴茎手术。由于随访时间少于 6 个月,4 例无复发的患者被排除在研究之外。数据包括疾病分期、细胞分化、肿瘤部位、保留阴茎手术类型和复发信息。
28 例原位癌和 28 例 T1 疾病患者的随访时间充足。总的复发率为 21.4%,原位癌和 T1 肿瘤的复发率相等(各为 21.4%)。平均±SD 复发时间为 4.28±2.81 年(范围 0.5 至 11)。超过 25%的复发发生在 5 年后。在截尾患者中,平均随访时间为 5.47±3.88 年(最长 16 年)。原位癌和 T1 肿瘤的复发时间无差异(p=0.738)。龟头的 T1 肿瘤复发风险略高(p=0.049)。在 5 年时,13.8%的风险患者出现晚期复发,平均复发时间为 7.25±2.62 年。没有原位癌患者出现浸润或转移。2 例 T1 疾病患者出现转移,3 例出现晚期转移。
保留阴茎手术是局部控制合适的原位癌和 T1 阴茎鳞状细胞癌的安全选择。原位癌复发可通过保留阴茎手术再次治疗。复发的 T1 肿瘤需要更积极的切除。我们的数据显示患者有明显的晚期复发,需要长期随访。